MEZO 24-hour amplitude reaches 52.1%: Low liquidity causes violent fluctuations
Bitget Pulse2026/04/26 16:02Volatility Overview
In the past 24 hours, MEZO's price rebounded from a low of $0.03588 to a high of $0.05457, currently reporting at $0.04324, reaching a swing of up to 52.1%. 24-hour trading volume is approximately $4-6.5 million, higher than the previous day, but overall liquidity remains low.
Brief Analysis of Abnormal Fluctuations
- Dominated by Low Liquidity: Bitget's monitoring shows that MEZO's price rebounded from $0.03425 to $0.05457 in the past 24 hours, a fluctuation of 59.3%, mainly due to low liquidity amplifying buying impact.
- Active Coinbase Spot Trading: Multiple price spike records were observed, such as a 7.85% jump to $0.04368 (volume $10.67K) and 8.29% to $0.04375 (volume $22.15K), fueling a short-term rally.
No clear official announcements, large on-chain whale transfers, or news events within 24 hours.
Market Views and Outlook
Community discussions mainly revolve around real-time price alerts, with Coinbase traders focusing on short-term spikes, but pullbacks (such as drops of 3.05%-4.12%) were also recorded. Mainstream sentiment is neutral to cautious. Analysts warn of high risks due to low liquidity, short-term volatility may persist, and there is no clear market forecast for the future.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for information purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
